Scholar Rock Overview

  • Founded
  • 2012
Founded
  • Status
  • Public
  • Employees
  • 145
Employees
  • Stock Symbol
  • SRRK
Stock Symbol
  • Share Price
  • $12.07
  • (As of Thursday Closing)

Scholar Rock General Information

Description

Scholar Rock Holding Corp is a biopharmaceutical company. It is engaged in the discovery and development of innovative medicines for the treatment of serious diseases including neuromuscular disorders, cancer, fibrosis, and anemia. Geographically, the company primarily operates in the United States. The company's lead product candidate is SRK-015 which is a highly selective, fully human, monoclonal antibody, with a mechanism of action that results in inhibition of the activation of the growth factor, myostatin, in skeletal muscle.

Contact Information

Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Stock Exchange
NAS
Primary Office
  • 301 Binney Street
  • 3rd Floor
  • Cambridge, MA 02142
  • United States
+1 (857) 000-0000
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Scholar Rock Stock Performance

(As of Thursday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$12.07 $11.89 $11.35 - $66.02 $420M 35.3M 238K -$3.59

Scholar Rock Financials Summary

In Thousands,
USD
TTM 31-Dec-2021 FY 2021 31-Dec-2021 FY 2020 31-Dec-2020 FY 2019 31-Dec-2019
EV 679,375 679,375 1,549,130 220,646
Revenue 18,816 18,816 15,403 20,492
EBITDA (129,172) (129,172) (84,992) (49,697)
Net Income (131,799) (131,799) (86,483) (51,000)
Total Assets 304,445 304,445 388,305 196,381
Total Debt 77,058 77,058 57,139 5,303
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Scholar Rock Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Scholar Rock‘s full profile, request access.

Request a free trial

Scholar Rock Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Scholar Rock Holding Corp is a biopharmaceutical company. It is engaged in the discovery and development of innovative m
Biotechnology
Cambridge, MA
145 As of 2021
00000
000000 - 000 00000

000000 0

idunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco l
0000 000000000
Burlingame, CA
00 As of 0000
00000
000000 - 000 00000

00000000

consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nu
0000000000000
Gaithersburg, MD
00 As of 0000
00000
0000 0000-00-00
00000000 00000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Scholar Rock Competitors (52)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Corvus Pharmaceuticals Formerly VC-backed Burlingame, CA 00 00000 000000 - 000 00000
000000000 Formerly VC-backed Gaithersburg, MD 00 00000 00000000 00000
000000 00000000000 Formerly VC-backed South San Francisco, CA 000 00000 00000000 00000
0000 00000000000 Formerly VC-backed Redwood City, CA 00 00000 000000&0 00000
00000000 Venture Capital-Backed San Carlos, CA 00 00000 00000000000 00000
You’re viewing 5 of 52 competitors. Get the full list »

Scholar Rock Patents

Scholar Rock Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
AU-2020216177-A1 Ltbp complex-specific inhibitors of tgfβ and uses thereof Pending 30-Jan-2019 00000000000
CA-3128042-A1 Ltbp complex-specific inhibitors of tgf.beta. and uses thereof Pending 30-Jan-2019 00000000000
US-20210047396-A1 Ltbp complex-specific inhibitors of tgfb and uses thereof Pending 30-Jan-2019 000000000
EP-3689905-A2 Ltbp complex-specific inhibitors of tgf-beta and uses thereof Pending 30-Jan-2019 00000000000 00
EP-3689905-A3 Ltbp complex-specific inhibitors of tgf-beta and uses thereof Pending 30-Jan-2019 C07K16/2863 0
To view Scholar Rock’s complete patent history, request access »

Scholar Rock Executive Team (16)

Name Title Board Seat Contact Info
Nagesh Mahanthappa Ph.D Chief Executive Officer & Board Member
Stuart Kingsley Chief Executive Officer, President & Board Member
Caryn Parlavecchio Chief Human Resources Officer
Gregory Carven Ph.D Chief Scientific Officer
Yung Chyung MD Chief Medical Officer
You’re viewing 5 of 16 executive team members. Get the full list »

Scholar Rock Board Members (14)

Name Representing Role Since
Akshay Vaishnaw Ph.D Self Board Member 000 0000
Amir Nashat Ph.D Polaris Partners Board Member 000 0000
David Hallal Self Chairman 000 0000
Jeffrey Flier MD Scholar Rock Board Member 000 0000
Joshua Reed Self Board Member 000 0000
You’re viewing 5 of 14 board members. Get the full list »

Scholar Rock Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Scholar Rock Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Scholar Rock‘s full profile, request access.

Request a free trial